Literature DB >> 3104015

The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II.

G P Ceda, R G Davis, R G Rosenfeld, A R Hoffman.   

Abstract

Hypothalamic-pituitary-end-organ axes are frequently controlled by long loop negative feedback homeostatic mechanisms. Insulin-like growth factor I (IGF-I), IGF-II, and insulin receptors have recently been described in normal and neoplastic rat and acromegalic human pituitary cells, a finding which suggests the possibility that somatomedins might exert feedback at the level of the anterior pituitary. To study the kinetics of this feedback response, we used perifused dispersed rat anterior pituitary cells to learn if somatomedins or insulin could inhibit GH-releasing hormone (GHRH)-stimulated GH secretion. Cells were exposed to hourly boluses of 1 nM GHRH with or without varying doses of IGF or insulin. IGF-I inhibited GHRH-elicited GH release with an IC50 of 6.5 nM; maximal inhibition (approximately 67%) was achieved with 10 nM IGF-I. IGF-II was a less potent hormone, with 10 nM inhibiting about 30% of GHRH-stimulated GH release. Slight inhibition of stimulated GH release (less than 15%) was seen when cells were treated with insulin, but only when doses of insulin of 10 nM or more were used. In conclusion, nanomolar concentrations of IGF-I and IGF-II inhibited GHRH-elicited GH release from perifused rat pituitary cells in a dose-dependent manner; and insulin was not an effective inhibitor of stimulated GH release at physiological peptide concentrations. In conjunction with our previous findings that the concentrations of IGF-I and IGF-II receptors greatly exceed that of insulin receptors on normal rat pituitary cells, we hypothesize that the GH-inhibiting action of high dose insulin is mediated through an IGF receptor.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3104015     DOI: 10.1210/endo-120-4-1658

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  16 in total

Review 1.  Molecular biology of the insulin-like growth factors. Relevance to nervous system function.

Authors:  J E Hepler; P K Lund
Journal:  Mol Neurobiol       Date:  1990 Spring-Summer       Impact factor: 5.590

2.  Direct effect of insulin and insulin-like growth factor-I on the secretory activity of rat pancreatic beta cells.

Authors:  C F Van Schravendijk; L Heylen; J L Van den Brande; D G Pipeleers
Journal:  Diabetologia       Date:  1990-11       Impact factor: 10.122

Review 3.  IGFs in the feedback control of GH secretion: Hypothalamic and/or pituitary action?

Authors:  G P Ceda
Journal:  J Endocrinol Invest       Date:  1995-10       Impact factor: 4.256

4.  Effects of GH and IGF-I administration on GHRH and somatostatin mRNA levels: I. A study on ad libitum fed and starved adult male rats.

Authors:  M C Ghigo; A Torsello; R Grilli; M Luoni; M Guidi; S G Cella; V Locatelli; E E Müller
Journal:  J Endocrinol Invest       Date:  1997-03       Impact factor: 4.256

Review 5.  The metabolic effects of growth hormone in adipose tissue.

Authors:  Valéria Ernestânia Chaves; Fernando Mesquita Júnior; Gisele Lopes Bertolini
Journal:  Endocrine       Date:  2013-02-21       Impact factor: 3.633

6.  Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.

Authors:  L Gianotti; J Ramunni; F Lanfranco; B Maccagno; R Giordano; F Broglio; M Maccario; E E Muller; E Ghigo; E Arvat
Journal:  J Endocrinol Invest       Date:  2001-02       Impact factor: 4.256

7.  Testosterone supplementation in older men restrains insulin-like growth factor's dose-dependent feedback inhibition of pulsatile growth hormone secretion.

Authors:  Johannes D Veldhuis; Daniel M Keenan; Joy N Bailey; Adenborduin Adeniji; John M Miles; Remberto Paulo; Mihaela Cosma; Cacia Soares-Welch
Journal:  J Clin Endocrinol Metab       Date:  2008-11-04       Impact factor: 5.958

8.  Exogenous growth hormone administration does not inhibit the growth hormone response to hexarelin in normal men.

Authors:  M Cappa; S Setzu; S Bernardini; D Carta; G Federici; A Grossi; S Loche
Journal:  J Endocrinol Invest       Date:  1995-11       Impact factor: 4.256

9.  Physiological levels of growth hormone fail to suppress growth hormone releasing hormone (1-29) NH2-stimulated growth hormone secretion in man.

Authors:  C Brain; D N Thakrar; P C Hindmarsh; C G Brook
Journal:  J Endocrinol Invest       Date:  1993-01       Impact factor: 4.256

10.  Pituitary Insulin: Insulin-Like Growth Factors.

Authors:  Shunichi Yokoyama; Lucia Stefaneanu; Kalman Kovacs
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.